Toshiba Corporation Selects Affymetrix Axiom Platform for Its Newly Launched Genotyping Service in Japan
December 01 2014 - 6:30AM
Business Wire
Affymetrix (NASDAQ: AFFX) announces its Axiom® Genotyping
Solution platform has been selected by Toshiba Corporation’s (TYO:
6502) Healthcare Company as the platform for its newly launched
genotyping service. Affymetrix collaborated with Toshiba to custom
design and manufacture the Japonica Array™, which is based on the
Axiom platform. This array contains unique genetic content
specifically optimized for the Japanese population. Toshiba has
launched this genotyping service as of Dec. 1, 2014 for Japanese
population genotyping studies primarily servicing universities,
hospitals, and other research agencies and institutes.
“After reviewing various microarray technology providers, we
selected Affymetrix’ Axiom platform for our genotyping service
based on its high throughput capability, cost effectiveness,
superior performance, and highly reproducible manufacturing
process. The team at Affymetrix worked closely with our scientists
in designing this array, which contains the genetic content
developed as the result of the collaboration with Tohoku
University. It was a pleasure collaborating with Affymetrix in the
development of Japonica Array™,” said Satoshi Tsunakawa, Corporate
Senior Vice President of Toshiba Corporation and President and CEO
of Toshiba’s Healthcare Company.
“We are very pleased to support Toshiba in delivering
high-quality and cost-effective genotyping service to enable
Japanese researchers to better understand the genetic markers
associated with diseases and response to therapy specific to the
Japanese population,” said Frank Witney, CEO and President of
Affymetrix. “Based on our long history of successful business in
Japan, it is clear that Japanese customers have a strong
appreciation for quality and expect superior performance and
reproducibility. This is a key strength for Affymetrix and we are
glad Toshiba holds these high standards as well. Working together,
we look forward to expanding the value of genetic information for
the Japanese population.”
Axiom Biobank Genotyping Solution is the platform of choice for
leading population genotyping studies such as UK Biobank, Million
Veteran Program, and others. To learn more about Axiom Genotyping
Solution, visit www.affymetrix.com/axiombiobank.
PLEASE NOTE: The Affymetrix logo, Affymetrix, and Axiom
are registered trademarks of Affymetrix, Inc. All other trademarks
and product names are the property of their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales
and distribution operations across Europe, Asia, and
Latin America. For more information about Affymetrix, please
visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
Media Contact:Mindy Lee-Olsen, 408-731-5523Vice
President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024